免疫万特

最新新闻

• 评级变动
  J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $53
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/5/27
• 评级变动
  LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• 评级变动
  A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• 评级变动
  Guggenheim Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/4/28
• 评级变动
  LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/23
• 评级变动
  A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $41 to $66
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• Truist Financial Maintains Immunovant(IMVT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49
  \u5e02\u573a\u8d44\u8baf · 2026/5/25
• 评级变动
  J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
  TipRanks · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。